Elanco Animal Health (NYSE:ELAN) Receives $33.00 Consensus Price Target from Brokerages

Elanco Animal Health (NYSE:ELAN) has been assigned an average recommendation of “Buy” from the fourteen ratings firms that are covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $33.00.

ELAN has been the topic of several analyst reports. Credit Suisse Group reiterated a “buy” rating on shares of Elanco Animal Health in a research report on Wednesday. Bank of America upgraded shares of Elanco Animal Health from a “neutral” rating to a “buy” rating and set a $34.00 price target on the stock in a research report on Thursday, December 19th. Raymond James initiated coverage on shares of Elanco Animal Health in a research report on Thursday, January 9th. They set a “market perform” rating on the stock. ValuEngine upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating in a research report on Wednesday, March 4th. Finally, TheStreet upgraded shares of Elanco Animal Health from a “d+” rating to a “c-” rating in a research report on Tuesday, December 24th.

Shares of NYSE:ELAN traded up $1.80 on Monday, reaching $21.42. 6,174,396 shares of the company’s stock were exchanged, compared to its average volume of 6,806,774. The company has a fifty day moving average of $26.33 and a 200-day moving average of $27.58. Elanco Animal Health has a twelve month low of $15.17 and a twelve month high of $35.46. The company has a market capitalization of $8.69 billion, a price-to-earnings ratio of 112.74, a PEG ratio of 1.24 and a beta of 0.81. The company has a current ratio of 2.90, a quick ratio of 1.62 and a debt-to-equity ratio of 0.42.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, February 19th. The company reported $0.23 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.23. Elanco Animal Health had a net margin of 2.21% and a return on equity of 7.33%. The firm had revenue of $787.00 million for the quarter, compared to analyst estimates of $790.83 million. During the same quarter in the prior year, the business posted $0.29 EPS. The business’s revenue was down 1.5% compared to the same quarter last year. As a group, equities research analysts forecast that Elanco Animal Health will post 1.11 EPS for the current fiscal year.

In related news, Director John P. Bilbrey acquired 3,000 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The stock was acquired at an average price of $25.15 per share, with a total value of $75,450.00. Following the purchase, the director now directly owns 8,016 shares in the company, valued at $201,602.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director R David Hoover acquired 3,900 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was bought at an average cost of $27.40 per share, with a total value of $106,860.00. Following the purchase, the director now owns 21,075 shares in the company, valued at $577,455. The disclosure for this purchase can be found here. Insiders have purchased a total of 15,000 shares of company stock worth $388,329 in the last quarter. 0.04% of the stock is currently owned by company insiders.

Large investors have recently modified their holdings of the stock. Andra AP fonden lifted its stake in Elanco Animal Health by 17.9% in the 3rd quarter. Andra AP fonden now owns 131,500 shares of the company’s stock valued at $3,497,000 after purchasing an additional 20,000 shares during the last quarter. State Street Corp lifted its stake in Elanco Animal Health by 46.3% in the 3rd quarter. State Street Corp now owns 9,763,351 shares of the company’s stock valued at $259,608,000 after purchasing an additional 3,087,565 shares during the last quarter. Amundi Pioneer Asset Management Inc. lifted its stake in Elanco Animal Health by 49.0% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 16,315,711 shares of the company’s stock valued at $480,499,000 after purchasing an additional 5,364,089 shares during the last quarter. Stifel Financial Corp raised its stake in shares of Elanco Animal Health by 12.7% during the third quarter. Stifel Financial Corp now owns 190,280 shares of the company’s stock valued at $5,037,000 after acquiring an additional 21,438 shares during the last quarter. Finally, Artemis Investment Management LLP bought a new position in shares of Elanco Animal Health during the fourth quarter valued at $8,844,000. 92.68% of the stock is owned by institutional investors and hedge funds.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.

Further Reading: Example of operating income, EBIT and EBITDA

Analyst Recommendations for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.